Biotechnology industries

Pharmaceutical industry

Oncolytics Biotech Inc. Announces Publication of Study Demonstrating Synergistic Effect of REOLYSIN and VEGF Inhibitors in Cancer Treatment

A groundbreaking study published in the Journal of Clinical Investigation has demonstrated the potential of combining oncolytic virotherapy with angiogenic cancer therapy to effectively treat cancer. The research, co-authored by Dr. Richard Vile of the Mayo Clinic and Dr. Kevin Harrington of the Institute of Cancer Research, shows that using

Pharmaceutical industry

Bio-Path Holdings Announces FDA Clearance for Phase I Clinical Trial of Liposomal Grb-2

Bio-Path Holdings, a publicly traded biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase I clinical trial of their lead cancer drug candidate, liposomal Grb-2. This development represents a significant milestone for the company, marking the transition from pre-clinical to

Pharmaceutical industry

Genentech Submits Supplemental Application for Actemra to Prevent Structural Joint Damage in Patients with Rheumatoid Arthritis

Genentech, Inc., a leading biotechnology company, has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Actemra (tocilizumab) to prevent structural joint damage and improve physical function in adults with moderately to severely active rheumatoid arthritis (RA). This application is based on

Pharmaceutical industry

GlaxoSmithKline Sued Over Patent for Cancer Treatment Arzerra

GlaxoSmithKline PLC (GSK) has been sued by U.S.-based biotech firms Genentech and Biogen Idec over a patent related to cancer treatment Arzerra that GSK and Danish biotech partner Genmab A/S are developing. The lawsuit was filed in a California court, alleging infringement of a patent granted to

Pharmaceutical industry

Tiny Nanoparticle Robots Deliver Cancer Therapy with Promising Results

U.S. researchers have successfully developed tiny nanoparticle robots that can navigate through a patient's blood and penetrate tumours, delivering a therapy that silences an essential cancer gene. This breakthrough, published in the journal Nature, hints at the potential of RNA interference (RNAi) as a new treatment approach

Pharmaceutical industry

Genentech Submits Supplemental Biologics License Application for ACTEMRA for Prevention of Structural Joint Damage in Rheumatoid Arthritis Patients

Genentech has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for ACTEMRA (tocilizumab) for the prevention of structural joint damage and improvement in physical function in adults with moderately to severely active rheumatoid arthritis. ACTEMRA was approved by the

Pharmaceutical industry

Astellas Pharma's $3.5 Billion Takeover Bid for OSI Pharmaceuticals Fails to Reflect Peak Annual Revenue Potential

Astellas Pharma's hostile takeover bid for OSI Pharmaceuticals Inc. has been criticized by OSI's Chief Executive Officer Colin Goddard, who argues that the $3.5 billion offer does not account for the cancer pill Tarceva's peak annual revenue potential of $7 billion. Goddard also

Pharmaceutical industry

Genentech Announces Topline Results of Phase III Trial for Avastin in Late Stage Prostate Cancer

Genentech, a member of the Roche Group, has announced the topline results of a Phase III trial investigating the use of Avastin in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer. The study, known as CALGB 90401, did not meet its primary objective of extending

Pharmaceutical industry

Conference Calls Scheduled for March 9, 2010

Conference calls scheduled for today at 5 to 6 p.m. Eastern Standard Time include companies such as Boston Beer Company Inc., ZipRealty Inc., Collective Brands Inc., and Jamba Inc. These calls are crucial for market trends, geopolitical conditions, news, and economic releases. FinancialWire provides comprehensive conference call schedules and

Pharmaceutical industry

FDA Approves Rituxan for Previously Untreated and Treated CLL

The U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL). CLL is a slow-growing cancer that affects nearly 90,000 people in the United States, accounting for one-third

Pharmaceutical industry

ImmunoCellular Therapeutics Receives Notice of Allowance for Monoclonal Antibody ICT-69

ImmunoCellular Therapeutics, a biotechnology company focused on developing immune-based therapies for cancer, announced today that it has received a Notice of Allowance for its monoclonal antibody ICT-69. This antibody targets multiple myeloma and ovarian cancers, demonstrating high specificity by targeting a novel cell surface antigen. The new patent allows for

Pharmaceutical industry

Spectrum Pharmaceuticals Enters into Co-Development and Commercialization Agreement for Belinostat

Spectrum Pharmaceuticals, a biotechnology company focused on oncology, has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor. Belinostat is currently in a registrational trial for relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and has been granted Orphan Drug and